Aim: To analyze the current use of antihypertensive drug classes in Japanese hypertensive patients stratified by age, highlighting differences between older and younger patients.
Introduction
Analyses of data from national surveys of the Japanese population over the 50-year period 1961−2010 have shown a clear downward trend in mean systolic blood pressure (BP) in all age groups of men and women. 1 This fall in BP is considered to be the main reason for the substantial decline in stroke mortality in the population over this period. 2 In 2010, there were an estimated 43 million individuals with hypertension in Japan. 1 This number is expected to escalate along with the rapid aging of society, increasing the number of patients at risk of stroke. 1 The 2011 National Health and Nutrition Survey of Japan reported hypertension prevalence of 66% in people aged 65-74 years, and 80% in people aged ≥75 years. 3 The 2014 Japanese Society of Hypertension (JSH) Guidelines for Management of Hypertension recommend calcium channel blockers (CCB), angiotensin II receptor blockers (ARB), angiotensin-converting enzyme (ACE) inhibitors and low-dose diuretics as first-line antihypertensive drugs. 3 In elderly patients, the guidelines recommend that antihypertensive treatment begin with half the usual dose of one drug and, if not sufficiently effective, add another drug to start combination therapy. 3 Target BP levels should be set at <140/90 mm Hg for patients aged <75 years, and at <150/90 mm Hg for patients aged ≥75 years.
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Methods

Data extraction period
The present retrospective study was carried out using the Medical Data Vision (MDV) nationwide database of anonymized medical health claims and administrative data, covering more than 15 million individuals treated as inpatients or outpatients at 174 hospitals in Japan participating in the Diagnostic Procedure Combination payment system (constituting 11% of all Diagnostic Procedure Combination hospitals). The database holds information on diagnoses, medical costs, prescriptions (including prescription dates) and, for some hospitals, blood test results.
Patients diagnosed with hypertension, whose details were entered into the MDV database, were the basis for the study (n = 123 414; 100%). Research began in May 2013 with data being collected for 1 year preceding the start date of the index period (April 2014 to March 2015). The index date was defined as the first day of prescription of an antihypertensive drug during the index period, with the index prescription being defined as the first antihypertensive prescription dispensed on the index date. The look-back and follow-up periods were defined as 1-year periods preceding and following the index date respectively. The study period ended in February 2016.
Patient disposition
A total of 59 867 patients met all the inclusion criteria and none of the exclusion criteria, and were included in the analysis (Fig. 1) . Patients who had been prescribed a loop diuretic or aldosterone antagonist, either as monotherapy or in combination, were excluded, as these prescriptions can be used for congestive heart failure or other edematous conditions.
Patients and comorbid disease classifications
Patients were classified into groups according to their age on the index date: <65 years, 65-74 years and ≥75 years. Patients were also classified by comorbidities of interest (diabetes, dyslipidemia, gout/hyperuricemia, renal diseases) and age.
Comorbid diseases and antihypertensive drugs were defined using International Classification of Diseases (ICD), ICD-10 5 and/or Anatomical Therapeutic Chemical (ATC) Classification System 6 codes.
End-points
The end-point was the prescription rate, defined as the incidence of prescription of an antihypertensive drug (for treatment of hypertension) during the index period.
Ethical considerations
Analyses were carried out using anonymous medical data, as all data are encrypted before entry into the MDV database. According to Ethical Guidelines for Epidemiological Research issued by the Japanese Ministry of Health, Welfare and Labor, ethics approval and informed consent were not applicable. Data were analyzed by IQVIA IMS Japan K.K. and stored in standalone (not connected to a local area network) personal computers that could be locked with a password.
Statistical analysis
Demographics, baseline comorbidities and the number of antihypertensive drugs prescribed were summarized using descriptive statistics, and presented as the mean and standard deviation (SD) for continuous data, and as number and percentages for categorical data. Prescription rates for each class of antihypertensive drug were presented as percentages for the overall population and for patient subgroups according to age, and according to age and comorbidities of interest. Analyses were carried out using SAS version 9.2 (SAS Institute, Cary, NC, USA).
Results
Patient demographics, comorbidities and the number of antihypertensive drugs prescribed are summarized in Table 1 . The mean age AE SD in the overall population (n = 59 867) was 70.0 AE 11.9 years. Patients were stratified into three pre-defined age groups: <65 years (n = 17 205, 28.8%), 65-74 years (n = 19 810, 33.1%) and ≥75 years (n = 22 852, 38.2%). There were more male (n = 34 044, 56.9%) than female (n = 25 823, 43.1%) patients in the overall population, although the proportion of females was higher in the ≥75 years age group (n = 11 511, 50.4%), and lower in the 65-74 years (n = 8069, 40.7%) and <65 years (n = 6243, 36.3%) age groups.
Patients were also stratified by age and major comorbid conditions: diabetes mellitus (n = 14 548, 24.3% of the overall population), dyslipidemia (n = 34 001, 56.8%), gout/hyperuricemia (n = 10 886, 18.2%) and renal disease (n = 5966, 10.0%). The proportion of patients with renal disease was higher in the ≥75 years age group (n = 2714, 45.5%), than in the 65-74 years (n = 1805, 30.3%) and <65 years (n = 1447, 24.3%) age groups.
Prevalences of comorbid heart disease (inpatient) and cerebrovascular disease (inpatient) were higher in the ≥75 years age group (61.8% and 23.9%, respectively) than in the 65-74 years (50.8% and 19.2%) and <65 years (40.2% and 13.5%) age groups.
The number of antihypertensive drugs prescribed during the index period in the overall population, and in each age group, is summarized in Table 1 . The mean number AE SD of oral antihypertensive drugs prescribed for patients in the overall population was 1.9 AE 1.0. The mean number AE SD of antihypertensive drugs prescribed increased marginally with advancing age, with values of 1.8 AE 1.0, 1.9 AE 1.0 and 2.0 AE 1.0, respectively, for patients aged <65, 65-74 and ≥75 years.
Prescription rates for each class of antihypertensive drugs per age group are summarized in Figure 2 . CCB and ARB were the most commonly prescribed drug classes, with prescription rates ranging from 61.9% to 70.4% and from 56.8% to 63.1%, respectively, across age groups. CCB were prescribed more often than ARB in the 65-74 years (66.9% vs 60.5%) and especially the ≥75 years (70.4% vs 56.8%) age groups. β-Blockers were prescribed to approximately 25% of patients in each age group. Loop diuretics were prescribed more often to patients aged ≥75 years (15.8%) than to those aged 65-74 years (8.3%) or <65 years (6.4%). Thiazide diuretics and ACE inhibitors were prescribed to approximately 10% and 9% of patients, respectively, across age groups. Prescription rates for aldosterone antagonists, α-blockers and direct renin inhibitors were low.
Prescription rates for antihypertensive drug classes prescribed as monotherapy or as combination therapy, per age group, are shown in Figure 3 . As monotherapy (Fig. 3a) , CCB were prescribed to a similar proportion of patients across age groups (18.4-20.2%). ARB were prescribed less frequently to patients aged ≥75 years (11.0%) than those aged <65 years (19.4%) or 65-74 years (15.6%). CCB + ARB was the most commonly prescribed two-drug combination (Fig. 3b) , and CCB + ARB + β-blocker was the most commonly prescribed three-drug combination (Fig. 3c) . Prescription rates for the five most commonly prescribed two-and three-drug combinations were broadly similar across age groups, except for more extensive use of "other" combinations in the ≥75 years age group. Prescription rates for each class of antihypertensive drug as index treatment according to comorbidity and stratified by age are shown in Figure 4 . Across comorbidities, the most commonly prescribed drug classes were CCB and ARB, followed by β-blockers. Prescription rates for all other drug classes were comparatively low and were broadly similar across comorbidity subgroups except for loop diuretics which were prescribed more often to patients aged ≥75 years compared with younger age groups, and were prescribed frequently to patients with comorbid renal diseases.
Discussion
The present study analyzed the current use of antihypertensive drug classes in nearly 60 000 hypertensive Japanese patients stratified by age group. There was a higher proportion of patients in the overall population aged ≥75 years (38.2%) compared with those aged 65-74 years (33.1%) or <65 years (28.8%).
Compared with younger age groups, the ≥75 year age group had a higher proportion of women, and a higher prevalence of renal disease, heart disease and cerebrovascular disease. These factors are relevant in interpreting the current use of antihypertensive drugs, as the choice of therapy would be influenced by the presence and severity of comorbid conditions, and patients' general performance status.
The mean number of antihypertensive drugs prescribed for patients in the overall population was 1.9 AE 1.0. Although the mean values did not differ appreciably among age groups, a trend was observed towards prescribing of more antihypertensive drugs with advancing age. A recent study of 400 patients attending a Japanese hypertension clinic reported that the number and classes of prescribed antihypertensive drugs were similar between patients aged <80 years and ≥80 years. 7 In the present study, we observed a trend towards greater use of three or more antihypertensive drugs concomitantly in patients aged ≥75 years compared with their younger counterparts.
The two most commonly prescribed classes of antihypertensive drugs in all age groups were CCB and ARB. These were also the two most commonly prescribed antihypertensive drug classes in a large Japanese survey carried out from 2005 to 2011, although that study did not stratify patients by age. 8 An analysis of 400 patients attending a Japanese hypertension clinic also reported that CCB (78%) and ARB (66%) were the most commonly prescribed antihypertensives. 7 In the current study, it was notable that the prescription rate for ARB as monotherapy was relatively low in patients aged ≥75 years (11.0% vs 20.0% for CCB), suggesting that physicians were tailoring their prescribing choices according to patient age. Older patients are generally presumed to have nephrosclerosis as a result of agingrelated physiological deterioration of renal function and a long-standing history of hypertension. 9 Thus, it is possible that prescribing physicians considered patients aged ≥75 years to be more prone to dehydration and more susceptible than younger patients to hyperkalemia or hyponatremia as an adverse effect of ARB. 10 Furthermore, CCB have no negative effects on glucose and/or lipid metabolism. 3 Collectively, these characteristics might explain the higher prescribing rate of CCB over ARB in patients aged 65-74 years, and especially in those aged ≥75 years. The UK's National Institute for Health and Care Excellence hypertension guidelines recommend CCB as initial therapy in persons aged >55 years. 11 A recently reported nationwide populationbased study from South Korea found results similar to the present results in prescription rates of CCB and ARB among three pre-defined age groups of adults (19-64 years), elderly (65-79 years) and very elderly (≥80 years). 12 In the current study, loop diuretics were prescribed more frequently to patients aged ≥75 years than to other age groups. The 2015 guidelines issued by the Japan Geriatrics Society for safe medication in elderly patients specify that loop diuretics belong to a drug category that is inferior in efficacy relative to safety and/or is determined to have safe alternatives (e.g. spironolactone); 13 certain α-and β-blockers also belong in this category. However, as evidenced in our own study population, patients aged ≥75 years tend to have a higher prevalence of comorbid heart disease and renal diseases, and, consequently, are commonly prescribed loop diuretics. A further interesting finding was the higher prescribing rate of two-and three-drug combinations apart from the five most common combinations in patients aged ≥75 years compared with younger age groups. In other words, prescribing for patients aged ≥75 years was complicated and individualized, which might be due to greater difficulties in selecting appropriate antihypertensive drugs and/or achieving blood pressure control in this age group. There were minimal differences by age in prescription rates for β-blockers, ACE inhibitors and thiazide diuretics. Given that each age group included a relatively large proportion of patients with comorbid heart disease, and that β-blockers were not necessarily prescribed to lower blood pressure, the study results do not allow us to draw conclusions about the use of β-blockers. We found low use of ACE inhibitors overall with no remarkable differences according to age (prescription rates of approximately 9.0% across age groups). Prescription rates for thiazide diuretics of approximately 10% across age groups suggested that their use is not influenced by patient age. Among hypertensive patients with diabetes mellitus, JSH guidelines recommend treatment with ARB or ACE inhibitors. 3 In the group aged ≥75 years with comorbid diabetes mellitus, the prescription rate for CCB was higher than that for ARB, suggesting that renin-angiotensin system (RAS) inhibitors are not always given priority over CCB when prescribing for patients with diabetes mellitus. However, the (total) proportion of patients with comorbid diabetes mellitus who received ARB and/or ACE inhibitors exceeded that of patients who were prescribed CCB, including in the group aged ≥75 years.
RAS inhibitors are recommended first-line therapy for diabetic patients with chronic kidney disease, irrespective of the presence of proteinuria. 3 For nondiabetic patients with chronic kidney disease, RAS inhibitors are recommended first-line therapy if proteinuria is present, whereas RAS inhibitors, CCB and diuretics are all options if proteinuria is absent. 3 In the present study, prescription rates for RAS inhibitors (especially ARB) were lower in patients aged ≥75 years with comorbid diabetes mellitus or renal diseases compared with younger age groups, and were lower in patients aged ≥75 years with comorbid diabetes mellitus or renal diseases compared with prescription rates for CCB. It must be noted, however, that the present study did not examine the presence of proteinuria or evaluate prescription rates in hypertensive patients with both diabetes mellitus and chronic kidney disease.
The present study had limitations with regard to generalizing the results to the hypertensive population as a whole. The MDV database collects data only from patients registered at hospitals with Diagnostic Procedure Combination-based payment systems and, as such, might not be representative of the entire Japanese hypertensive population. A patient's treatment history cannot be traced accurately if he/she moves between healthcare providers, and limited information is collected on laboratory values including BP. Furthermore, the dosages of antihypertensive drugs used by patients were not taken into consideration. Finally, it is possible that, for some patients, their actual diagnosis might have differed from that recorded on the medical receipt and that antihypertensive drugs might have been prescribed for purposes other than lowering BP. In particular, the relatively high incidence of comorbid heart disease in the study population might have had some influence on the observed prescribing patterns.
The study results showed that drugs selected for patients aged ≥75 years differed from those selected for patients aged <75 years, in particular CCB, ARB and loop diuretics. Antihypertensive prescription patterns also varied according to comorbidity. In patients with diabetes mellitus, physicians did not always prioritize RAS inhibitors over CCB. The prescription rate for loop diuretics as part of combination therapy was especially high among patients aged ≥75 years with comorbid renal disease.
In view of the observed differences among age groups with respect to the prevalence of comorbid conditions and male-to-female gender ratio, further research in this area is warranted. Longitudinal analysis is required to determine whether antihypertensive drug therapy is being initiated at low doses in older patients in accordance with the JSH guidelines. 3 Furthermore, the absence of data on blood pressure values precluded making comparisons about the success of antihypertensive therapy in patients aged ≥75 years relative to younger age groups.
